# ROME Therapeutics

> Biotech targeting the genomic 'repeatome' for cancer and autoimmune disease.

## Why it is interesting

ROME maps repetitive DNA once dismissed as junk to find innate-immune drug targets — ARCH and GV incubated the company before a16z joined later rounds.

## Profile

- **Stage:** series-b
- **Status:** private
- **Industries:** biotech-life-sciences
- **Coverage:** full
- **Last updated:** 2026-07-24

## Key facts

- Series A (Apr 2020): $50M co-led by GV and ARCH Venture Partners (ROME press)
- Series B extension (Sep 2023): $72M with a16z, ARCH, GV participation (ROME press)
- Source: https://rometx.com/press-releases/rome-therapeutics-launches-to-develop-novel-therapies-for-cancer-and-autoimmune-diseases-by-harnessing-the-power-of-the-repeatome/

## Investors in our directory

- https://venturecapitaltracker.com/fund/andreessen-horowitz
- https://venturecapitaltracker.com/fund/arch-venture-partners

## Related articles

- https://venturecapitaltracker.com/2026-a16z-hot-portfolio-companies

---
Source: https://venturecapitaltracker.com/startup/rome-therapeutics